Wealth Alliance Has $112,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Wealth Alliance lifted its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 60.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,000 shares of the biotechnology company’s stock after acquiring an additional 12,000 shares during the period. Wealth Alliance’s holdings in Heron Therapeutics were worth $112,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HRTX. Victory Capital Management Inc. raised its holdings in shares of Heron Therapeutics by 30.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares during the period. Panagora Asset Management Inc. acquired a new position in Heron Therapeutics during the 4th quarter worth approximately $236,000. Orchard Capital Management LLC raised its stake in Heron Therapeutics by 4.7% during the 4th quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock worth $3,814,000 after buying an additional 100,603 shares during the period. Diversified Trust Co bought a new position in Heron Therapeutics in the first quarter worth approximately $66,000. Finally, Commonwealth Equity Services LLC grew its stake in Heron Therapeutics by 3.1% in the first quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock valued at $938,000 after acquiring an additional 10,122 shares during the period. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Stock Performance

HRTX stock opened at $2.06 on Friday. The company has a market capitalization of $310.35 million, a P/E ratio of -3.38 and a beta of 1.80. Heron Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.93. The business has a 50-day simple moving average of $2.33 and a two-hundred day simple moving average of $2.77.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $36.02 million during the quarter, compared to analyst estimates of $35.35 million. During the same period in the prior year, the business earned ($0.35) EPS. As a group, sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HRTX has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a research report on Wednesday, August 7th. Rodman & Renshaw initiated coverage on shares of Heron Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 price target for the company.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.